glp-1 receptor agonist drugs in development research Agonists Market Report 2025-2033, By Product, Molecule, and Geo History of glucagon-like peptide-1 receptor

Obesity is a chronic disease associated with increased risk of obesity-related complications and mortality

Glucagon-like peptide 1 (GLP-1) is a cleavage product of the pre-proglucagon gene which is expressed in the -cells of the pancreas, the L-cells of the intestine, and neurons located in the caudal brainstem and hypothalamus

With the rising incidence of obesity, there is a growing demand for new therapies which can effectively manage body weight and improve health

Retatrutide vs Semaglutide: Evidence-based comparison of the investigational triple GIP/GLP-1/glucagon agonist versus the FDA-approved GLP-1 agonist

With the emergence of various classes of blood glucose-lowering agents, choosing the appropriate drug for each patient is emphasized in diabetes management

Glucagon-like peptide (GLP)-1 receptor agonists are the cornerstone in the treatment of hyperglycemia in many people suffering from type 2 diabetes (T2D)